

TCGA Survey Page 1 🖰 [SURVEY PREVIEW MODE] Clinical Proteomic Tumor Analysis Consortium Survey: TCGA - Google Chrome SurveyMonkey, Inc [US] https://www.surveymonkey.com/s.aspx?PREVIEW_MODE=DO_NOT_USE_THI Westat^{*} Clinical Proteomic Tumor Analysis Consortium Survey: TCGA Survey for Clinical Proteomic Tumor Analysis Consortium (CPTAC, Phase II) Survey of The Cancer Genome Atlas (TCGA) researchers The National Cancer Institute (NCI) launched the Clinical Proteomic Technologies for Cancer (CPTC) initiative in 2006 (Phase I) to specifically address barriers in proteomics research to ensure any findings are due to the biology and not analytical variability. Building upon the accomplishments of CPTC Phase I, the Clinical Proteomic Tumor Analysis Consortium (CPTAC) program (Phase II) was launched in August 2011 to apply the analytical workflows developed in Phase I to better understand cancer biology. CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. CPTAC has developed a range of products, including antibodies and a centralized data repository for the dissemination of proteomic data to the public. NCI has retained Westat, an independent research organization, to conduct a survey of CPTAC (Phase II) that will provide information on the degree to which CPTAC is meeting its goals and identify opportunities for program improvement. The views of individuals involved with The Cancer Genome Atlas (TCGA) are critical to understanding and improving the efforts of CPTAC. Participation in this survey is voluntary, but your views are important and we hope you will complete it even if you know little about CPTAC. All data will be reported to NCI in aggregate form. No reports will contain findings linked to individual respondents or institutions. If you have questions about this survey, please contact Dr. Eden Segal at edensegal@westat.com or 240-314-7583. If you have questions about your rights and welfare as a research participant, please call the Westat Human Subjects Protections office at 1-888-920-7631. Please leave a message with your full name, the name of this study-CPTAC Survey for NIH-and a phone number beginning with the area code. Someone will return your call as soon as possible. If you have questions about the CPTAC program itself, contact Dr. Tara Hiltke at hiltket@mail.nih.gov or 301-OMB No.: 0925-0842: Expiration Date: 09/30/2014 Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0048). Do not return the completed form to this address. If you agree to participate in this short survey click Next, below.

Next




[Q3 Not at all familiar skips to survey Page 7]

TCGA Survey Page 3




TTCC 4 C

ICGA Survey Page 4 S ISURVEY PREVIEW MODE] Clinical Proteomic Tumor Analysis Consortium Survey: TCGA - Google Chrome	_
SurveyMonkey, Inc [US] https://www.surveymonkey.com/s.aspx?PREVIEW_MODE=DO_NOT_USE_THIS_LINK_FOR_COLLECTION&sm=	%2bJg548kC1
Westat	^
Clinical Proteomic Tumor Analysis Consortium Survey: TCGA	
5. Which of the following CPTAC resources available to the public have you used? (select all that apply) Informatics tools developed by CPTAC	
Affinity reagents (monoclonal antibodies) The NCI makes affinity reagents available to the public for research purposes through the Developmental Studies Hybridoma bank at the University of Iowa at Iow http://dshb.biology.uiowa.edu/.	cost at
The NCI antibody portal The NCI antibodies and affinity reagents characterization data is available to the public through the NCI antibody portal at http://antibodies.cancer.gov.	
Proteogenomic data available through the CPTAC Data Coordinating Center The CPTAC data portal is a centralized data repository for the dissemination of proteomic data collected by the Proteome Characterization Centers for the CPTA program. All data are freely available for secondary analysis, subject to data use guidelines. It is available at https://cptac-data-portal.georgetown.edu/cptacPublic	
In-depth characterization of monoclonal antibodies for cancer-related protein targets by NCI. NCI offers affinity reagent, characterization and distribution through the CPTAC data portal provided approximately annually. More information is available at http://proteomics.cancer.gov/newsevents/eprotein/june2013/researcher-opportunities/acptargetrequest	
CPTAC assay portal The Assay Portal serves as a public resource of well-characterized quantitative mass spectrometry-based proteomic assays comprising standard operating procedure reagents, and assay validation data. It is available at http://cptac.cancer.gov/	dures,
None	
Other (please specify)	
Prev Next	
	-



TCGA Survey Page 6



TCGA Survey Page 7

	A SURVEY PAGE / RVEY PREVIEW MODE] Clinical Proteomic Tumor Analysis Consortium Survey: TCGA - Google Chrome	_
	rveyMonkey, Inc [US] https://www.surveymonkey.com/s.aspx?PREVIEW_MODE=DO_NOT_USE_THIS_LINK_FOR_COLLECTION&sm=%	
341	TITE TO THE TOTAL THE TOTA	zbigb lokel
	Westat	
-	, worth	
Clini	ical Proteomic Tumor Analysis Consortium Survey: TCGA	
The I	last set of questions asks about you and your work.	
10. V	What is your main area of expertise? (select all that apply)	
	Bioinformatics	
	Cancer biology	
	Clinical chemistry	
	Experimental design	
	Genomics	
	Oncology	
	Proteomics	
	Statistics	
	Other (please specify)	
		=
11. A	At what type of institution do you work? (select one)	
	Academic	
) Clinical	
	Government /Military	
	Industry	
	Other (please specify)	
	If there is anything else you would like to share about the CPTAC program, including what improvements might make program efforts more usefucer research, please do so in the box below.	ıl to
	See rescaled, predict do se in the box below.	
	Prev Done	
		+

Display a "Thank You" Page?

No, do not display a thank y	ou page. After f	finishing the survey,	respondents will	proceed directly	y to the completion	n option you s	pecify
below.							

0	Yes.	displa	y a thank	you page	after finishing	the survey	L
---	------	--------	-----------	----------	-----------------	------------	---

Thank	you	very	much	for	your	participation.	